Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
Effects of Bacille Calmette-GuÉrin after the first demyelinating event in the CNS.
Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.
Reverse causality behind the association between reproductive history and MS.
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.
Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Inflammation high-field magnetic resonance imaging.
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination.
MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis.
A facilitation and co-ordination therapy approach to the treatment of multiple sclerosis.
Regulation of myelination in the Central Nervous System by Nuclear Lamin B1 and non-coding RNAs.
Comparisons of Costs between Black Caribbean and White British Patients with Advanced Multiple Sclerosis in the UK.
Higher burden of migraine compared to other neurological conditions: results from a cross-sectional study.
Effective combination of minocycline and interferon-beta in a model of multiple sclerosis.
Care of patients with multiple sclerosis.
[Optic neuritis: diagnosis, treatment and clinical implications].
The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus.
Clinical designs of recent robot rehabilitation trials.
A Simple Sign for Recognizing Off-Axis OCT Measurement Beam Placement in the Context of Multicentre Studies.
Pages
« first
‹ previous
…
265
266
267
268
269
270
271
272
273
…
next ›
last »